Welcome to our dedicated page for Tectonic Therapeutic news (Ticker: TECX), a resource for investors and traders seeking the latest updates and insights on Tectonic Therapeutic stock.
Tectonic Therapeutic, Inc. (NASDAQ: TECX) is a clinical-stage biotechnology company headquartered in Watertown, Massachusetts, focused on therapeutic proteins and antibodies that modulate G-protein coupled receptors (GPCRs). The TECX news stream highlights how the company advances its GPCR-targeted biologic pipeline, particularly in pulmonary hypertension and hereditary bleeding disorders.
Company press releases frequently cover clinical trial milestones for TX45, a long-acting Fc-relaxin fusion protein that activates the RXFP1 receptor. Updates include interim and complete Phase 1b data in Group 2 pulmonary hypertension in heart failure with preserved and reduced ejection fraction (PH-HFpEF and PH-HFrEF), the ongoing APEX Phase 2 trial in PH-HFpEF, and plans for a Phase 2 study in Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD). Tectonic also reports on the planned clinical development of TX2100, a GPCR-targeting biotherapeutic for Hereditary Hemorrhagic Telangiectasia (HHT).
Investors following TECX news will also see financial results and operating updates released with each quarter, as well as announcements about private placements, index inclusion such as entry into the Russell 3000® Index, and participation in healthcare and investor conferences. These items provide context on Tectonic’s cash position, research and development spending, and engagement with the investment community.
This news page aggregates Tectonic’s press releases and related disclosures so readers can review clinical data readouts, trial initiation plans, financial updates, and conference appearances in one place. For anyone tracking GPCR-focused biologic development and pulmonary hypertension programs, the TECX news feed offers a focused view of the company’s reported progress and key events over time.
Tectonic Therapeutic (NASDAQ: TECX) said management will participate in two investor conferences in March 2026: TD Cowen on March 4, 2026 in Boston and Leerink on March 11, 2026 in Miami.
Each appearance is a fireside chat with CEO Alise Reicin, MD, available via webcast and replay on the company website for ~90 days; management will also hold one-on-one meetings by request.
Tectonic Therapeutic (NASDAQ: TECX) reported clinical progress and year-end cash and expense figures. TX45 showed positive Part B Phase 1b topline results with a 29.2% reduction in PCWP and 17.3% improvement in cardiac output. TX45 moved into two Phase 2 trials (PH-ILD opened for screening; APEX topline expected 2026). TX2100 randomized its first healthy volunteer in a Phase 1a trial in Feb 2026. Cash and cash equivalents were $253.8 million as of Dec 31, 2025, providing runway into Q4 2028.
Tectonic Therapeutic (NASDAQ: TECX) appointed François Nader, M.D., MBA, as an independent director and Chair of the Board, effective April 1, 2026. Terry McGuire will resign as Chair but remain a board member until the company’s anticipated June 2026 annual meeting.
Dr. Nader brings over 30 years of biotech leadership, board experience including Moderna, and a track record of strategic transactions with multiple acquired companies.
Tectonic Therapeutic (NASDAQ: TECX) will host a virtual key opinion leader event on Feb 24, 2026 from 11:00 a.m. to 12:30 p.m. ET to discuss TX2100, a GPCR antagonist in preclinical development for Hereditary Hemorrhagic Telangiectasia (HHT).
The program includes a mechanistic review, preclinical evidence, clinical context from Hanny Al-Samkari, MD, and a live Q&A. Tectonic expects to initiate a Phase 1a healthy-volunteer trial of TX2100 in Q1 2026.
Tectonic Therapeutic (NASDAQ: TECX) announced management will participate in two investor conferences in December 2025. Key events: a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 at 3:30 PM ET in New York with Alise Reicin, MD, President and CEO, and one-on-one investor meetings at the Evercore 8th Annual Healthcare Conference on December 3, 2025 in Miami.
The Piper Sandler session will be webcast and available under the company’s Investors “Events & Presentations” page at www.tectonictx.com, with a replay accessible for approximately 90 days. Investors should contact their Piper Sandler or Evercore representatives to request one-on-one meetings.
Tectonic Therapeutic (NASDAQ: TECX) reported positive topline Part B data from the TX45 Phase 1b trial in 14 PH-HFrEF patients, showing a 29.2% reduction in PCWP and a 17.3% improvement in cardiac output. In CpcPH subgroups, TX45 showed a 19.7% PVR reduction (PVR≥3 WU) and 10.3% PVR reduction (PVR≥2 WU). The company expects TX45 PH-ILD Phase 2 to start in 2026 and topline APEX Phase 2 results in 2026. TX2100 Phase 1 for HHT is expected to begin in Q1'2026 after completion of IND-enabling GLP studies. Financials: $268.4M cash at Sept 30, 2025, projected runway into Q4'2028; R&D expense $16.9M and net loss $19.0M for Q3'2025.
Tectonic Therapeutic (NASDAQ: TECX) announced positive topline Phase 1b Part B results for TX45 in patients with Group 2 pulmonary hypertension associated with HFrEF on October 29, 2025. In 14 enrolled patients a single IV dose produced meaningful hemodynamic improvements including PCWP -29.2%, TPR -29.2%, mPAP -19.3% and CO +17.3%, with echocardiography showing persistent gains at day 29 (LVEF +19.4%, RVFAC +20.3%, TAPSE/SPAP +36.3%). TX45 was well tolerated with no serious or severe adverse events reported. Results support potential expansion into PH‑HFrEF while the company continues the APEX Phase 2 trial with topline 2026 readout expected.
Tectonic Therapeutic (NASDAQ: TECX), a clinical stage biotech company specializing in GPCR-focused therapeutic proteins and antibodies, has announced its participation in three major healthcare investor conferences in September 2025.
The company will attend the Wells Fargo Healthcare Conference on September 3 for investor meetings, the Cantor Global Healthcare Conference on September 4 featuring a fireside chat with CFO Daniel Lochner and CBO Marc Schwabish, and the Morgan Stanley Global Healthcare Conference on September 10 with CEO Alise Reicin. Both fireside chats will be webcast and available for replay on the company's website.
Tectonic Therapeutic (NASDAQ: TECX) reported Q2 2025 financial results and provided key clinical updates. The company ended Q2 with $287.4 million in cash, projecting runway into Q4'2028. Notable developments include plans to initiate a Phase 2 trial for TX45 in PH-ILD in 2026, completion of enrollment in TX45 Phase 1b Part B trial for PH-HFrEF, and continued enrollment in the TX45 APEX Phase 2 trial.
Complete results from TX45 Phase 1b Part A showed promising outcomes, including a 19% reduction in pulmonary capillary wedge pressure and 18.5% improvement in cardiac output. The company's pipeline expansion includes TX2100, targeting hereditary hemorrhagic telangiectasia, with Phase 1 trial initiation expected in Q1'2026.
Q2 2025 financial results showed R&D expenses of $17.2 million and a net loss of $20.0 million, reflecting increased investment in clinical development.
Tectonic Therapeutic (NASDAQ: TECX), a clinical stage biotech company specializing in therapeutic proteins and antibodies for GPCR modulation, has been added to the Russell 3000® Index following the 2025 Russell US Indexes annual reconstitution, effective June 30, 2025.
The inclusion automatically places Tectonic in either the Russell 1000® Index or Russell 2000® Index, along with corresponding growth and value style indexes. The Russell 3000® Index membership, which is determined by market capitalization rankings and style attributes, will remain in place for one year.